The 2025 Guideline for the Management of Patients With Acute Coronary Syndromes: Asian Perspective [0.03%]
2025年急性冠状动脉综合征患者的管理指南：亚洲视角
Mitsuaki Sawano,Xin Du,Nathan D Wong et al.
Mitsuaki Sawano et al.
The 2025 ACC/AHA Guideline for Acute Coronary Syndromes: A View From Down Under [0.03%]
从澳洲视角看2025年急性冠状动脉综合征的美国心脏病学会/美国心脏协会指南
John F Beltrame,Stephen J Nicholls
John F Beltrame
Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline: What It Is and What It Might Have Been [0.03%]
2025年ACC / AHA急性冠状动脉综合征指南中脂质管理成熟的现状及未来趋势展望
Julia Brandts,Kausik K Ray
Julia Brandts
Mechanical Circulatory Support in Acute Myocardial Infarction-Cardiogenic Shock: 2025 Acute Coronary Syndrome Guideline in Context [0.03%]
急性心肌梗死心脏源性休克的机械循环支持：2025年急性冠状动脉综合征指南中的相关问题
Karthik Murugiah,Theresa A McDonagh,David J Cohen et al.
Karthik Murugiah et al.
ACS Management Guidelines: Tradition, Innovation, and the Gaps in Between [0.03%]
ACS管理指南：传统、创新以及两者之间的差距
Mohamad Alkhouli,David J Moliterno
Mohamad Alkhouli
The 2025 ACS Guideline Update Endorses Ticagrelor Monotherapy ≥1 Month After DAPT Post-PCI: The Unbearable Lightness of Ticagrelor Monotherapy [0.03%]
2025年ACS指南更新支持PCI术后DAPT至少1个月后单用替格瑞洛：单用替格瑞洛的“不可承受之轻”
Roxana Mehran,Angelo Oliva,Marco Valgimigli
Roxana Mehran
The 2025 Guideline Update Endorses Ticagrelor Monotherapy After ≥1 Month of DAPT Post-PCI in Patients With ACS: Is the Evidence Conclusive? [0.03%]
2025年指南更新支持ACS患者PCI术后≥1个月DAPT期间使用替格瑞洛单药治疗：证据充分了吗？
Sanjay Kaul,James M Brophy
Sanjay Kaul
Perspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline [0.03%]
2025年急性冠脉综合征管理指南双联抗血小板治疗选择和时长推荐展望
Dennis T Ko,Rasha K Al-Lamee,Behnood Bikdeli et al.
Dennis T Ko et al.